Link Cell Therapies

Executive Summary

Link Cell Therapies is a preclinical-stage biotechnology company developing next-generation, off-the-shelf allogeneic cell therapies for oncology and autoimmune diseases. Founded in 2021 and based in Cambridge, MA, the company leverages advanced gene editing and engineering to create enhanced immune cell products that aim to overcome key limitations in cell therapy, such as safety, efficacy, and accessibility. With $60 million in total funding, Link Cell is poised to advance its lead programs toward clinical development. The company's platform focuses on allogeneic approaches to enable scalable, cost-effective treatments that can reach broader patient populations. Despite being in the preclinical stage, Link Cell's technology has attracted investor interest, and the company is actively progressing toward regulatory filings and early clinical studies to validate its platform.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Program60% success
• Q3 2026Preclinical Data Presentation at Major Conference80% success
• Q2 2027Potential Collaboration or Licensing Deal40% success